S&P 500   3,852.36
DOW   32,920.46
QQQ   305.57
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Closing prices for crude oil, gold and other commodities
Harley-Davidson Inc. Stock, Is It Time To Buy?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street's rally rolls on, led by torrid tech stocks
Meta Platforms, Allegiant rise; Qorvo, Canada Goose fall
S&P 500   3,852.36
DOW   32,920.46
QQQ   305.57
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Closing prices for crude oil, gold and other commodities
Harley-Davidson Inc. Stock, Is It Time To Buy?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street's rally rolls on, led by torrid tech stocks
Meta Platforms, Allegiant rise; Qorvo, Canada Goose fall
S&P 500   3,852.36
DOW   32,920.46
QQQ   305.57
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Closing prices for crude oil, gold and other commodities
Harley-Davidson Inc. Stock, Is It Time To Buy?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street's rally rolls on, led by torrid tech stocks
Meta Platforms, Allegiant rise; Qorvo, Canada Goose fall
S&P 500   3,852.36
DOW   32,920.46
QQQ   305.57
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Humble Mineral at the Heart of the EV Revolution (Not Lithium) (Ad)
Closing prices for crude oil, gold and other commodities
Harley-Davidson Inc. Stock, Is It Time To Buy?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street's rally rolls on, led by torrid tech stocks
Meta Platforms, Allegiant rise; Qorvo, Canada Goose fall
NYSE:GMED

Globus Medical - GMED Stock Forecast, Price & News

$78.59
+1.51 (+1.96%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$76.97
$78.87
50-Day Range
$68.95
$77.08
52-Week Range
$52.60
$81.78
Volume
448,071 shs
Average Volume
423,515 shs
Market Capitalization
$7.85 billion
P/E Ratio
52.05
Dividend Yield
N/A
Price Target
$79.00

Globus Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
0.5% Upside
$79.00 Price Target
Short Interest
Bearish
6.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.04mentions of Globus Medical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$562,500 Sold Last Quarter
Proj. Earnings Growth
14.29%
From $2.03 to $2.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

383rd out of 1,030 stocks

Surgical & Medical Instruments Industry

39th out of 105 stocks

GMED stock logo

About Globus Medical (NYSE:GMED) Stock

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Stock News Headlines

The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
15 Largest Orthopedic Companies in the World
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
7 Analysts Have This to Say About Globus Medical
Company News for Nov 10, 2022
Needham Reaffirms Their Buy Rating on Globus Medical (GMED)
BTIG Keeps Their Buy Rating on Globus Medical (GMED)
Globus Medical Reports Third Quarter 2022 Results
Globus Medical (GMED) Q3 Earnings Lag Estimates
Globus Medical's Earnings Outlook
Globus Medical Inc - Ordinary Shares - Class A
Could Globus Medical Be the Best Healthcare Stock?
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

GMED Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$91.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$149.19 million
Pretax Margin
20.11%

Debt

Sales & Book Value

Annual Sales
$958.10 million
Cash Flow
$2.85 per share
Book Value
$17.15 per share

Miscellaneous

Free Float
75,471,000
Market Cap
$7.85 billion
Optionable
Optionable
Beta
0.99

Key Executives

  • Daniel T. ScavillaDaniel T. Scavilla
    President, Chief Executive Officer & Director
  • Keith W. PfeilKeith W. Pfeil
    CFO, Chief Accounting Officer & Senior VP
  • Kelly G. HullerKelly G. Huller
    Secretary, Senior VP & General Counsel
  • Brian Kearns
    Senior Vice President-Business Development













GMED Stock - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GMED shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price forecast for 2023?

8 Wall Street research analysts have issued twelve-month target prices for Globus Medical's shares. Their GMED share price forecasts range from $71.00 to $91.00. On average, they predict the company's share price to reach $79.00 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2023?

Globus Medical's stock was trading at $74.27 at the beginning of 2023. Since then, GMED stock has increased by 5.8% and is now trading at $78.59.
View the best growth stocks for 2023 here
.

Are investors shorting Globus Medical?

Globus Medical saw a drop in short interest in December. As of December 30th, there was short interest totaling 4,750,000 shares, a drop of 5.6% from the December 15th total of 5,030,000 shares. Based on an average daily trading volume, of 588,800 shares, the days-to-cover ratio is currently 8.1 days. Approximately 6.2% of the shares of the stock are short sold.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) posted its quarterly earnings results on Tuesday, November, 8th. The medical device company reported $0.50 earnings per share for the quarter, missing the consensus estimate of $0.52 by $0.02. The medical device company had revenue of $254.15 million for the quarter, compared to analysts' expectations of $252.94 million. Globus Medical had a net margin of 15.55% and a trailing twelve-month return on equity of 11.59%.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of $2.03-$2.03 for the period, compared to the consensus estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.02 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Boston Trust Walden Corp (0.66%), Pembroke Management LTD (0.59%), Allspring Global Investments Holdings LLC (0.40%), Fort Washington Investment Advisors Inc. OH (0.19%), Exchange Traded Concepts LLC (0.17%) and New York State Common Retirement Fund (0.14%). Insiders that own company stock include Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $78.59.

How much money does Globus Medical make?

Globus Medical (NYSE:GMED) has a market capitalization of $7.85 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.51 on an earnings per share basis.

How many employees does Globus Medical have?

The company employs 2,400 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042.

This page (NYSE:GMED) was last updated on 2/3/2023 by MarketBeat.com Staff